Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 9;1(1):20-3.
doi: 10.3109/21556660.2012.655815. eCollection 2012.

Individualized treatment with infliximab therapy in children with Crohn's disease support shorter time intervals between infusions

M Sommar  1 , S Eksborg  2 , H Hildebrand  3 , L Grahnquist  3
Affiliations

Individualized treatment with infliximab therapy in children with Crohn's disease support shorter time intervals between infusions

M Sommar et al. J Drug Assess. .

Abstract

Objectives: To study the effect of an individualized treatment approach with regard to dosage intervals between infliximab infusions on the clinical outcome of pediatric Crohn's disease (CD).

Patients and methods: A retrospective analysis of medical records of all pediatric patients with CD who had been treated with infliximab between 1999 and 2007 in two Swedish counties, where an individualized treatment approach had been applied.

Results: Twenty-nine patients were included in the study. The number of infusions varied from 2 to 47 (median: 8). Nineteen patients received more than 5 infusions and 13 patients received more than 10 infusions. Most of the patients did not stay in remission when the dosage interval was 8 weeks or longer.

Conclusions: An individualized treatment approach, based on the physician's desire to treat, resulted in shorter dosage intervals than 8 weeks between infliximab infusions in a majority of pediatric patients with CD. The retrospective design of the study must be taken into account when interpreting the results.

Keywords: Children; Clinical outcome; Crohn’s disease; Infliximab; Maintenance therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
All infusions given to patients eligible for individualized therapy.
Figure 2.
Figure 2.
Remission rates of all groups of patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Hildebrand H, Finkel Y, Grahnquist L, et al. Changing pattern of pediatric inflammatory bowel disease in Northern Stockholm 1990-2001. Gut 2003;52:1432-4 - PMC - PubMed
    1. Turunen P, Kolho KL, Auvinen A, et al. Incidence of inflammatory bowel disease in Finnish children 1987-2003. Inflamm Bowel Dis 2006;12:677-83 - PubMed
    1. Van der Zaag-Loonen HJ, Casparie M, Taminau JAJM, et al. The incidence of pediatric inflammatory bowel disease in the Netherlands: 1999–2001. J Pediatr Gastroenterol Nutr 2004;38:302-7 - PubMed
    1. Armitage E, Drummond HE, Wilson DC, et al. Increasing incidence of juvenile-onset Crohn’s disease and ulcerative colitis in Scotland. Eur J Gastroenterol Hepatol 2001;13:1439-47 - PubMed
    1. Malaty HM, Fan X, Opekun AR, et al. Rising incidence of inflammatory bowel disease among children: a 12 year study. J Pediatr Gastroenterol Nutr 2010;50:27-31 - PubMed

LinkOut - more resources